Hyperuricemia
Conditions
Interventions
Group A: Participants will be received 20mg/day of febuxostat for 12 weeks. After that participants will be received 100mg/day of allopurinol for 12 weeks without wasuout periods.
Group B: Participant
Sponsors
Department of Cardiovascular Medicine, Juntendo University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with hyperuricemia who have treated with allopurinol and have serum uric acid levels of 7.0 mg/dL or higher. 2) Patients who have eGFR of 30 mL/min/1.73m2 or higher. 3) Patients who give informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients who have contraindication of febuxostat treatment. 2) Patients with secondary hyperuricemia. 3) Patient who have systolic blood pressure of 160mmHg or higher, or diastolic blood pressure of 100mgHg or higher. 4) Patients with AST and ALT elevation more than twice the institutional standard. 5) Patients who have had coronary heart disease and cerebrovascular disease within 6 months. 6) Patients treated with mercaptopurine hydrate or azathioprine 7) Breast-feeding woman 8) Patients judged to be unsuitable participants by physician-in-charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) %change of serum uric acid levels 2) Endothelial function by Endo-PAT | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Oxidative stress marker (ie. nitrotyrosine, ADMA and MDA-LDL) 2) Office blood pressure (Ambulatory Blood Pressure Monitoring in possible cases) | — |
Countries
Japan
Contacts
Public ContactKazunori Shimada
Juntendo University Hospital Department of Cardiovascular Medicine
Outcome results
None listed